These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29723075)

  • 1. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
    Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
    Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
    Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
    PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.
    Sadowski MC; Pouwer RH; Gunter JH; Lubik AA; Quinn RJ; Nelson CC
    Oncotarget; 2014 Oct; 5(19):9362-81. PubMed ID: 25313139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis.
    Grube S; Dünisch P; Freitag D; Klausnitzer M; Sakr Y; Walter J; Kalff R; Ewald C
    J Neurooncol; 2014 Jun; 118(2):277-287. PubMed ID: 24789255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
    Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
    Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.
    Tyan YS; Lee YP; Chuang HY; Wang WH; Hwang JJ
    Biosci Rep; 2021 May; 41(5):. PubMed ID: 33974005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line.
    Cioccoloni G; Aquino A; Notarnicola M; Caruso MG; Bonmassar E; Zonfrillo M; Caporali S; Faraoni I; Villivà C; Fuggetta MP; Franzese O
    J Chemother; 2020 Feb; 32(1):30-40. PubMed ID: 31775585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas.
    Agostini M; Almeida LY; Bastos DC; Ortega RM; Moreira FS; Seguin F; Zecchin KG; Raposo HF; Oliveira HC; Amoêdo ND; Salo T; Coletta RD; Graner E
    Mol Cancer Ther; 2014 Mar; 13(3):585-95. PubMed ID: 24362464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules.
    Kant S; Kumar A; Singh SM
    Biochim Biophys Acta; 2012 Nov; 1820(11):1764-73. PubMed ID: 22877747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
    Lupu R; Menendez JA
    Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orlistat Reduces Proliferation and Enhances Apoptosis in Human Pancreatic Cancer Cells (PANC-1).
    Sokolowska E; Presler M; Goyke E; Milczarek R; Swierczynski J; Sledzinski T
    Anticancer Res; 2017 Nov; 37(11):6321-6327. PubMed ID: 29061815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
    Mullen GE; Yet L
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype.
    Kant S; Kumar A; Singh SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):294-302. PubMed ID: 24060750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal.
    Chuang HY; Chang YF; Hwang JJ
    Biomed Pharmacother; 2011 Jul; 65(4):286-92. PubMed ID: 21723078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
    Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy.
    Sankaranarayanapillai M; Zhang N; Baggerly KA; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):136-47. PubMed ID: 22886728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors.
    Angeles TS; Hudkins RL
    Expert Opin Drug Discov; 2016 Dec; 11(12):1187-1199. PubMed ID: 27701891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway.
    Chuang HY; Lee YP; Lin WC; Lin YH; Hwang JJ
    Sci Rep; 2019 Sep; 9(1):13284. PubMed ID: 31527721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine.
    Ross J; Najjar AM; Sankaranarayanapillai M; Tong WP; Kaluarachchi K; Ronen SM
    Mol Cancer Ther; 2008 Aug; 7(8):2556-65. PubMed ID: 18723500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.
    Yang CS; Matsuura K; Huang NJ; Robeson AC; Huang B; Zhang L; Kornbluth S
    Oncogene; 2015 Jun; 34(25):3264-72. PubMed ID: 25151963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.